DUBLIN, March 12, 2021 / PRNewswire / – The report “Global Drug Delivery Devices Market (2020-2025) by Device Type, Management Path, Application, End User, Vehicle View, Geography, Competitive Analysis and Covid-19 Impact by Ansoff Study” was added ResearchAndMarkets.com’s offering.
The Global Drug Delivery Devices Market is considered USD 21.1 Bn in 2020 and is expected to arrive USD 27.3 Bn by 2025, growing at a CAGR of 5.2%.
Market dynamics
Key factors, such as the rising number of children combined with chronic illnesses such as diabetes, cancer, etc., have led to a growth in drug delivery mechanisms. The rise in non-communicable diseases has also led to a demand for non-invasive drug delivery methods. In addition, the growth of biology contributes significantly to the market of drug delivery devices.
However, factors such as drug recall and biocompatibility issues with increased side effects appear to be hindering the growth of the drug delivery device market. In addition, the time it takes to approve novel drugs is also hampering the growth of drug delivery machines due to the subsequent delays in delivery.
Market view
The Global Drug Delivery Devices Market is further segmented by device type, administration route, application, end-user, vehicle vision, and Geography.
By device type, the market is classified as smart pills, inhalers, drug eluting stents, safety syringes, portable drug delivery devices, transdermal packs, and others. Among all, the smart pills sector is considered to hold the highest share of the market.
According to Route Administration, the market is classified as Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal, Topical, and others. Among all, the verbal route of administration is considered to maintain the highest share of the market.
By Application, the market is classified as Oncology, Infectious Diseases, Respiratory Diseases, Diabetes, Cardiovascular Diseases, Autoimmune Diseases, Central Nervous System Disorders, and others. Among all, the diabetes sector is estimated to hold the highest share of the market during the forecast period.
With end-user, the market is categorized as Hospitals, Diagnostic Centers, Surgical Centers / Clinics, Home Care Settings, and others. Among all, the hospital sector has the highest market share.
With Vehicle Outlook, the market is classified as hydrogel, micelle, dendrimer, nanoparticle, liposomes, scaffold, niosomes, and mesoporous products. Among all, the nanoparticle sector is considered to hold the highest share of the market.
By Geography, North America expects to lead the market.
Recent Developments
1. 3M have relaunched their drug delivery systems through Kindeva, a global contract manufacturing / development company with a focus on drug delivery projects. This is the new independent entity created with Altair following the sale of the drug delivery systems units to Altair Capital Partners for USD 650 Mn – 4th May 2020
2. Bayer enters into an agreement with Exscientia to identify and make good use of modern lead structures for potential drug candidates in the treatment of cardiovascular disease and oncological.- 22 January 2020
Company Profiles
Some of the companies covered in this report 3M Company, AstraZeneca PLC, Becton, Dickinson, Boehringer Ingelheim group, GlaxoSmithKline plc, Insulet Corporation, Medtronic Plc, Sulzer Ltd. and West Pharmaceuticals Services, Inc.
Key topics covered:
1 Description of the report
2 Research Methodology
3 Executive Minutes
4 Market outlook
4.1 Introduction
4.2 Market Dynamics
4.2.1 Drivers
4.2.1.1 Growing geriatric population and rising illnesses
4.2.1.2 Increased demand for non-invasive drug delivery methods
4.2.1.3 Growth in the biological markets
4.2.2 Barriers
4.2.2.1 High issues of drug calling
4.2.2.2 Biocompatibility issues
4.2.2.3 It takes a long time for novel drugs to be approved
4.2.3 Opportunity
4.2.3.1 Growth in nanotechnology and technological advances
4.2.3.2 Growing R&D investments
4.2.4 Challenges
4.2.4.1 Inefficiency in the delivery of intractable drugs
4.2.4.2 Lack of trained professionals to administer the drugs
4.3 Motions
5 Market Analysis
5.1 Porter’s Five Force Review
5.2 Impact of COVID-19
5.3 Ansoff Matrix Study
6 Global Drug Delivery Devices Market, By Device Type
6.1 Introduction
6.2 Smart Pills
6.3 Inhalers
6.4 Drug Eluting Stents
6.5 Safety Courtship
6.6 Implantable Drug Delivery Device
6.7 Transdermal packs
6.8 Other
7 Global Drug Delivery Devices Market, By Route of Administration
7.1 Introduction
7.2 Beul
7.3 Injection
7.4 Transdermal
7.5 Injectable
7.6 Ocular
7.7 Nasal
7.8 Subjective
7.9 Other
8 Global Drug Delivery Devices Market, By Demand
8.1 Introduction
8.2 Oncology
8.3 Infectious diseases
8.4 Respiratory diseases
8.5 Diabetes
8.6 Cardiovascular diseases
8.7 Self-defense diseases
8.8 Disorders of the Central Nervous System
8.9 Other
9 Global Drug Delivery Devices Market, By End User
9.1 Introduction
9.2 Hospital
9.3 Diagnostic Centers
9.4 Surgery Centers / Clinics
9.5 Home Care Situation
9.6 Other
10 Global Drug Delivery Equipment Market, With Vehicle Outlook
10.1 Introduction
10.2 Hydrogel
10.3 Micelle
10.4 Dendrimer
10.5 Nanoparticle
10.6 Liposome
10.7 Scaffold
10.8 Mesoporous Stuth
10.9 Niosomes
11 Global Drug Delivery Devices Market, According to Geography
12 Competitive Landscape
12.1 IGR Competitive Quadrant
12.2 Market segment analysis
12.3 Competitive Position
12.3.1 Mergers & Acquisitions
12.3.2 Agreement, Collaboration, & Partnerships
12.3.3 Launch and development of new product
12.3.4 Investment & Funding
13 Company Profiles
- Pfizer, Inc.
- Johnson & Johnson Services, Inc.
- F. Hoffmann-La Roche, Earr
- Novartis AG
- 3M
- Bayer AG
- NV uniQure
- Shenzhen (SiBiono) GeneTech Co. Ltd. (Hubei Tongji Benda Ebei Pharmaceuticals)
- Antares Pharma, Inc.
- GlaxoSmithKline plc
- AstraZeneca PLC
- Becton Dickinson
- Boehringer Ingelheim Group
- Consort Medical plc (Recipharm Group)
- Corporal Insulet
- Medtronic Plc
- Sulzer Limited.
- Western Pharmaceutical Services, Inc.
- Generex Biotechnology
- Panacea Pharmaceuticals Inc.
- Pharma Aptar
- Koninklijke Philips NV
- Nemera
- Biocorp Production.
- Eli Lilly and Co.
For more information about this report, visit https://www.researchandmarkets.com/r/kr6la3
Contact the media:
Research and Markets
Laura Wood, Senior Manager
[email protected]
For EST Office Hours Call + 1-917-300-0470
For US / CAN Toll Free Call + 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Fax USA: 646-607-1907
Fax (outside the US): +353-1-481-1716
SOURCE Research and Markets
Related Links
http://www.researchandmarkets.com